Treffer 1 - 6 von 6 für Suche 'Kavanaugh, Pascale', Suchdauer: 1,44s Treffer weiter einschränken
  1. 1
    Activity and flexibility of alcohol dehydrogenase in organic solvents

    Activity and flexibility of alcohol dehydrogenase in organic solvents von Guinn, R. Mark, Skerker, Paul S., Kavanaugh, Pascale, Clark, Douglas S.


    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  2. 2
    Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial

    Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial von McInnes, Iain B, Behrens, Frank, Mease, Philip J, Kavanaugh, Arthur, Ritchlin, Christopher, Nash, Peter, Masmitja, Jordi Gratacós, Goupille, Philippe, Korotaeva, Tatiana, Gottlieb, Alice B, Martin, Ruvie, Ding, Kevin, Pellet, Pascale, Mpofu, Shephard, Pricop, Luminita

    Veröffentlicht in The Lancet (British edition)

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  3. 3
    Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results from the Phase 3 FUTURE 1 Study

    Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results from the Phase 3 FUTURE 1 Study von Mease, Philip J., Kavanaugh, Arthur, Reimold, Andreas, Tahir, Hasan, Rech, Juergen, Hall, Stephen, Geusens, Piet, Pellet, Pascale, Delicha, Eumorphia Maria, Pricop, Luminita, Mpofu, Shephard

    Veröffentlicht in ACR open rheumatology

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  4. 4
    Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial (vol 395, pg 1496, 2020)

    Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial (vol 395, pg 1496,... von McInnes, I. B., Behrens, F., Mease, P. J., Kavanaugh, Arthur, Ritchlin, Christopher, Nash, Peter, Masmitja, Jordi Gratacos, Goupille, Philippe, Korotaeva, Tatiana, Gottlieb, Alice B., Martin, Ruvie, Ding, Kevin, Pellet, Pascale, Mpofu, Shephard, Pricop, Luminita

    Veröffentlicht in The Lancet (British edition)

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  5. 5
    258 Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5-year efficacy and safety results from the FUTURE 1 Phase 3 trial

    258 Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5-year efficacy and safety results from the FUTURE 1 Phase 3 trial von Tahir, Hasan, Mease, Philip J, Kavanaugh, Arthur, Reimold, Andreas, Rech, Jürgen, Hall, Stephen, Geusens, Piet, Pellet, Pascale, Delicha, Eumorphia Maria, Pricop, Luminita, Mpofu, Shephard

    Veröffentlicht in Rheumatology (Oxford, England)

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  6. 6
    Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial

    Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial von Mease, Philip J, Kavanaugh, Arthur, Reimold, Andreas, Tahir, Hasan, Rech, Jürgen, Hall, Stephen, Geusens, Piet, Pellet, Pascale, Delicha, Evie Maria, Mpofu, Shephard, Pricop, Luminita


    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: